Featured

FDA Approves Genentech's Susvimo for Diabetic Retinopathy

Genentech announced FDA approval of Susvimo (ranibizumab injection) 100 mg/mL for treating diabetic retinopathy (DR). Susvimo, delivered via a Port D...

Home/KnolSights/Regulatory Approvals/FDA Approves Genentech's Susvimo for Diabetic Retinopathy